NL-OMON55638已完成2 期
Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis - AC-058B202
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients who completed study treatment at their regular Week 24 (EOT) visit
- •within the core study (AC-058B201)., 2. Signed informed consent for
- •participating in the extension study.
排除标准
- •1. Patients meeting any of the study-specific criteria for permanent
- •discontinuation of study drug, or patients receiving any of the prohibited
- •concomitant medication., 2. Any other clinically relevant medical or surgical
- •condition, which, in the opinion of the investigator, would put the patient at
- •risk by participating in the extension study.
研究者
相似试验
进行中（未招募）
1 期
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosisrelapsing multiple sclerosisMedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2012-000540-10-LVActelion Pharmaceuticals Ltd1,100
进行中（未招募）
1 期
An international study, which is an extension to protocol AC 058B201, with the aim to study how safe and efficacious is the long-term treatment with ponesimod in three different doses in patients with relapsing-remitting multiple sclerosis.EUCTR2009-011470-15-GBACTELION Pharmaceuticals Ltd353
进行中（未招募）
1 期
Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)Relapsing multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000541-12-HUActelion Pharmaceuticals Ltd.600
进行中（未招募）
1 期
Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)EUCTR2012-000541-12-FIActelion Pharmaceuticals Ltd.600
进行中（未招募）
不适用
Multicenter, randomized, double-blind, parallel-group extension to study AC-058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ACT-128800, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis.EUCTR2009-011470-15-ITActelion Pharmaceuticals Ltd400